Given that the clinical investigation involves an FDA-regulated drug product, the next assessment is to determine whether an Investigational New Drug Application (IND) is needed. The regulations at 21 CFR 312.2(b)(1) address exemptions from an IND for a clinical investigation of a drug product that is lawfully marketed in the US, and states the following: